Fundraising FoxDracen Pharmaceuticals
Baltimore, US · Founded 2016 · 5 known investors
Find your way into Dracen Pharmaceuticals
Sign up to see every warm intro you have to Dracen Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Dracen Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment. Its lead candidate, sirpiglenastat (DRP-104), is in clinical trials for advanced solid tumors including KEAP1/NFE2L2-altered non-small cell lung cancer.
Founders & leadership
Dracen Pharmaceuticals was founded in 2016 by Robert Wild.
Board
Investors · 5
How we know: i&i Biotech Fund's portfolio page · Not right? Tell us
How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$19.4M disclosed across 3 rounds · 2018–2023
▶$2.3MraisedAug 2023 · 6 investors · BiotechnologyRule 506(b)
- Asher RubinExecutive Officer
- Drew Pardoll, M.D., Ph.D.Director
- Dennis M. BilskiExecutive Officer
- Jonathan LeffDirector
- Offering amount
- $2.8M
- Amount sold
- $2.3M
- Minimum investment
- $2.7K
- Proceeds to insiders
- $45K
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.6MraisedNov 2021 · 8 investors · BiotechnologyRule 506(b)
- Asher RubinExecutive Officer
- Dennis BilskiExecutive Officer
- Thomas M. EstokExecutive Officer, Director
- Drew Pardoll, M.D., Ph.D.Director
- Jonathan LeffDirector
- Offering amount
- $17M
- Amount sold
- $8.6M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$8.5MraisedJan 2018 · 9 investors · BiotechnologyRule 506(b)
- Drew Pardoll, M.D., Ph.D.Director
- Thomas M. EstokExecutive Officer, Director
- Jonathan LeffDirector
- Asher RubinExecutive Officer
- Robert JacksonDirector
- Offering amount
- $40.5M
- Amount sold
- $8.5M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Dracen Pharmaceuticals.
Frequently asked questions
- What does Dracen Pharmaceuticals do?
- Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment. Its lead candidate, sirpiglenastat (DRP-104), is in clinical trials for advanced solid tumors including KEAP1/NFE2L2-altered non-small cell lung cancer.
- Who founded Dracen Pharmaceuticals?
- Dracen Pharmaceuticals was founded by Robert Wild in 2016.
- Who are Dracen Pharmaceuticals's investors?
- Dracen Pharmaceuticals's investors include Biotech Investments S.R.O, i&i Biotech Fund, OUP (Osage University Partners), Deerfield Management Company, Sofinnova Ventures.
- How much funding has Dracen Pharmaceuticals raised?
- Dracen Pharmaceuticals has disclosed $19.4M raised across 3 rounds.
- Where is Dracen Pharmaceuticals headquartered?
- Dracen Pharmaceuticals is headquartered in Baltimore, US.